Mizuho Securities Upgrades Valeant Pharmaceuticals (VRX) to Buy; Limited Downside
Tweet Send to a Friend
Mizuho Securities upgraded Valeant Pharmaceuticals (NYSE: VRX) from Neutral to Buy with a price target of $155.00, citing limited downside.Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
